References
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-7. PubMed | Google Scholar
- Pignon JM. Translocation bcr-abl : méthodes diagnostiques
et interêt clinique. Annale de Biologie clinique. 2001; 56(1) : 57-9. PubMed | Google
Scholar
- Irenee Messanh Kueviakoe, Essohana Padaro, Kossi Agbetiafa,
Yao Layibo, Malewè Kolou, Ahoefa Vovor, Akuete Segbena. Hematological Malignancies:
analysis of myelogram results over 21 years in Lome Teaching Hospitals. Clinical
Medicine Research. 2015; Vol4 (4): 111-115.
- Diop S, Ndoura A, Toure Fall AO, Thiam D, Diakhate L. Bone Marrow aspiration in diagnosis of hemopathies in Dakar, Senegal. Dakar Med. 2004; 49(2): 106-9. PubMed | Google Scholar
- Mukiibi JM, Nyirenda CM, Paul B et al. “Chronic
myeloid leukaemia in central Africans”. East Afr Med J. 2003; 80 (9):
470 -5. PubMed | Google
Scholar
- Dokekias AE, Malanda F, Mbalawa CH. Chronic myeloid leukaemia: what's the future therapy in Black Africa? Tunis Med. 2003; 81(3): 172-9. PubMed
- De Souza C, Vigorito A. Validation of the EBMT risk score in chronic myeloid in leukaemia in Brazil and allogeneic transplant. Haematologica. 2005; 90 (2): 932 -7. PubMed | Google Scholar
- Tardieu S, Brun- Strang C, Berthaud P et al. “Management of chronic myeloid leukelmia in France: a multicentered cross-sectional study on 538 patients”. Pharmacoepidemiol Drug Saf. 2005; 14 (8): 545-53. PubMed | Google Scholar
- Sureda A, Carrasco M.“Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukaemia. Haematologica”. 2003; 88 (11): 1213-20. PubMed | Google Scholar
- Tolo Diebkilé A, Koffi KG, Sawadogo GD et al. Impact thérapeutique de l'interféron alpha dans la prise en charge des patients de leucémie myéloïde chronique. Mali Med. 2010 ; tome XXV (n°1) : 22-27. PubMed
- Inokuchi K, Futaki M, Dan K, Nomura T. Possible correlation of b3-a2-type bcr-abl messenger RNA defined by semiquantitative RT-PCR to platelet and megakaryocyte counts in Philadelphia-positive chronic myelogenous leukemia. Intern Med. 1994 Apr; 33(4):189-92. PubMed | Google Scholar
- Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, Tanabe Y, Ohki I, Dan K, Ozawa K et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991 Dec 15;78(12):3125-7. PubMed | Google Scholar
- Ouédraogo SM, Hien F, Millogo A et al. Place des hémopathies malignes en service de médecine interne du CHU SOURO SANOU (Burkina-Faso).Mali Med. 2011;Tome XXVI( n° 3) : 17. PubMed
- Tanzer, Guilhot F. Leucémie myéloïde chronique en hématologie par BERNARD DREYFUS. Ed Flammarion. 1999; 620-642. In press
- Teillet F, Thiebaud, Dubreuil M. Etude de la leucémie
myéloïde chronique. Encyclo Med Chir. 1986; Paris (France); Sang 13011 B20;
10. In press
- Brousted A. La leucémie myéloïde chronique in NAJMAN.
Ed Ellipse; précis des maladies du sang. 1994; tome II Paris:24-41. PubMed
- Martiat P, Ifrah N, Rassol F, Morgan G, Giles F, Gow J, Goldman JM. Molecular analysis of Philadelphia positive essential thrombocythemia. Leukemia. 1989; 41(3):363-367. PubMed | Google Scholar